Thomas Chan was named Chief Accounting Officer of GoodRx Holdings, Inc. As of November 6, 2026, GoodRx Holdings, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 3, 2026 to April 24, 2026, naming 1 appointment and 1 departure (Form 8-K, April 24, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like GoodRx Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
GoodRx Holdings, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-03 to 2026-04-24. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as GoodRx Holdings, Inc. files it.
Also on the record for GoodRx Holdings, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 26, 2026 | Stake report, Schedule 13D/A, by Francisco Partners IV, L.P. | 32.9% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| October 30, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 9.33% of the class | 5%+ stakes | Source |
| October 16, 2025 | Stake report, Schedule 13D/A, by Spectrum Equity VII, L.P. | — | 5%+ stakes | Source |
| September 8, 2025 | Stake report, Schedule 13D/A, by Spectrum Equity VII, L.P. | 8.28% of the class | 5%+ stakes | Source |
| July 3, 2025 | Stake report, Schedule 13D/A, by Spectrum Equity VII, L.P. | 12.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs GoodRx Holdings, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on GoodRx Holdings, Inc. and the records around it.
GoodRx Holdings, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch GoodRx Holdings, Inc.
Get an email when GoodRx Holdings, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on GoodRx Holdings, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on GoodRx Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on GoodRx Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-24 | In | Chief Accounting Officer | 8-K, 2026-04-24 | ||
| 2026-04-03 | Out | 2026-03-31 | 8-K, 2026-04-03 |
Who leads GoodRx Holdings, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Accounting Officer: Thomas Chan, appointed (filed 2026-04-24).
New leaders reset buying decisions — get the Full Report on GoodRx Holdings, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Accounting Officer at GoodRx Holdings, Inc., with the record behind each one.
Find candidates like Chief Accounting Officer at GoodRx Holdings, Inc.Every change, in the filing's words
Appointed: Thomas Chan, Chief Accounting Officer
Chief Accounting Officer Appointment On April 23, 2026, the Board of Directors (the "Board") of GoodRx Holdings, Inc. (the "Company") appointed Thomas Chan, Vice President, Corporate Controller of the Company as the Company's Chief Accounting Officer and designated Mr. Chan as the principal accounting officer of the Company, in each case effective immediately.
- Mr. Chan, 40, joined the Company in October 2020 and has served in various controllership and financial reporting roles, including as our Vice President, Corporate Controller from February 2024 to April 2026; Vice President, Accounting & Reporting from May 2023 to February 2024; Vice President, Financial Reporting & Quality from July 2022 to May 2023; and other accounting roles of increasing responsibility from October 2020 to July 2022.
- Prior to joining the Company, Mr. Chan served in various audit and assurance roles at Deloitte & Touche, LLP since July 2011, most recently as an Audit & Assurance Senior Manager.
- Mr. Chan holds a B.A. in Business Administration, with an emphasis in accounting, from California State University, Fullerton, and is a Certified Public Accountant in the State of California.
- In connection with his appointment, the Board approved an annual base salary increase to $310,000, with a target annual bonus of 40% of his base salary.
- In addition, Mr. Chan will be granted (i) a restricted stock unit award ("RSU Award") having an aggregate value of $131,250 and (ii) a performance-based restricted stock unit award ("PSU Award") having an aggregate value of $43,750 under the Company's 2020 Incentive Award Plan.
- We currently expect each award will be granted on the first trading day of the first "open window" that occurs following the Effective Date.
Departing: Ian T. Clark, effective 2026-03-31
On March 31, 2026, Ian T. Clark notified GoodRx Holdings, Inc. (the "Company") of his decision to resign as a member of the Company's Board of Directors (the "Board"), including his service on the Board's Nominating & Governance Committee, effective as of March 31, 2026.
- Mr. Clark has indicated to the Company that his decision to resign is not the result of any disagreement with the Company or its management on any matter relating to the Company's operations, policies or practices.
- Board Membership Update On April 2, 2026, in order to achieve an equal balance of membership among the classes of directors as a result of Mr. Clark's departure, the Board determined to move Wendy Barnes, Chief Executive Officer, President and Director of the Company, from Class I, with a term expiring at the 2027 annual meeting of stockholders, to Class III, with a term expiring at the 2026 annual meeting of stockholders.
- On April 1, 2026, Ms. Barnes, who served as a Class I director, tendered her resignation as a director, effective upon her election by the Board as a Class III director.
- The resignation and immediate re- election of Ms. Barnes was effected solely to rebalance the Board's classes and, for all other purposes, Ms. Barnes's service on the Board is deemed to have continued uninterrupted.
- The Board now consists of three directors in each of Classes I, II, and III.
Tools for this story
Each opens in a new tab, filled in for GoodRx Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.